0001193125-21-324438 | 10-Q | XBRL Viewer

Restricted Net Assets (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2021	Sep. 30, 2021
Restricted net assets
Statutory reserves	$ 0	$ 0

Label	Element	Value
Additional Milestone Payments	zlab_AdditionalMilestonePayments	$ 36,000,000,000
Additional Milestone Payments	zlab_AdditionalMilestonePayments	136,000,000
Additional Milestone Payments	zlab_AdditionalMilestonePayments	173,000,000
Additional Milestone Payments	zlab_AdditionalMilestonePayments	37,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	15,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	25,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	20,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	25,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	25,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	5,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	20,000,000
Payment Of Up front Fees For License Agreement	zlab_PaymentOfUpFrontFeesForLicenseAgreement	6,000,000
Issuance Cost Adjustment For Secondary Listing	zlab_IssuanceCostAdjustmentForSecondaryListing	1,000
Issuance Cost Adjustment For Secondary Listing	zlab_IssuanceCostAdjustmentForSecondaryListing	65,000
Issuance Cost Adjustment For Secondary Listing	zlab_IssuanceCostAdjustmentForSecondaryListing	65,000
Issuance Cost Adjustment For Secondary Listing	zlab_IssuanceCostAdjustmentForSecondaryListing	5,634,000
Issuance Cost Adjustment For Secondary Listing	zlab_IssuanceCostAdjustmentForSecondaryListing
Issuance Cost Adjustment For Secondary Listing	zlab_IssuanceCostAdjustmentForSecondaryListing
Accrued Rebate To Distributors Current	zlab_AccruedRebateToDistributorsCurrent	10,803,000
Accrued Rebate To Distributors Current	zlab_AccruedRebateToDistributorsCurrent	7,067,000
Future Contingent Milestone Payments To Be Made Upon Achievement	zlab_FutureContingentMilestonePaymentsToBeMadeUponAchievement	1,386,000,000
Future Contingent Milestone Payments To Be Made Upon Achievement	zlab_FutureContingentMilestonePaymentsToBeMadeUponAchievement	273,000,000
Future Contingent Milestone Payments To Be Made Upon Achievement	zlab_FutureContingentMilestonePaymentsToBeMadeUponAchievement	4,878,738,000
Increase Decrease In Value Added Taxes Receivable	zlab_IncreaseDecreaseInValueAddedTaxesReceivable	1,249,000
Increase Decrease In Value Added Taxes Receivable	zlab_IncreaseDecreaseInValueAddedTaxesReceivable	$ 6,845,000
Number Of Milestone Payments	zlab_NumberOfMilestonePayments	1
Number Of Milestone Payments	zlab_NumberOfMilestonePayments	1
Number Of Milestone Payments	zlab_NumberOfMilestonePayments	2
Number Of Milestone Payments	zlab_NumberOfMilestonePayments	3
Number Of Milestone Payments	zlab_NumberOfMilestonePayments	1
Number Of Milestone Payments Accrued	zlab_NumberOfMilestonePaymentsAccrued	1
Number Of Milestone Payments Accrued	zlab_NumberOfMilestonePaymentsAccrued	2
Revenue From Contract With Customer Adjustments for Compensation to Distributors	zlab_RevenueFromContractWithCustomerAdjustmentsForCompensationToDistributors	$ 0
Revenue From Contract With Customer Adjustments for Compensation to Distributors	zlab_RevenueFromContractWithCustomerAdjustmentsForCompensationToDistributors	22,009,000
Revenue From Contract With Customer Adjustments for Compensation to Distributors	zlab_RevenueFromContractWithCustomerAdjustmentsForCompensationToDistributors	0
Revenue From Contract With Customer Adjustments for Compensation to Distributors	zlab_RevenueFromContractWithCustomerAdjustmentsForCompensationToDistributors	0
Land Use Rights Net Noncurrent	zlab_LandUseRightsNetNoncurrent	7,749,000
Land Use Rights Net Noncurrent	zlab_LandUseRightsNetNoncurrent	7,908,000
Milestone Payments	zlab_MilestonePayments	1,000,000
Milestone Payments	zlab_MilestonePayments	4,000,000
Milestone Payments	zlab_MilestonePayments	2,000,000
Milestone Payments	zlab_MilestonePayments	$ 2,000,000
License Agreement Date And Year	zlab_LicenseAgreementDateAndYear	2019-06
License Agreement Date And Year	zlab_LicenseAgreementDateAndYear	2020-07
License Agreement Date And Year	zlab_LicenseAgreementDateAndYear	2021-01
License Agreement Date And Year	zlab_LicenseAgreementDateAndYear	2017-12
License Agreement Date And Year	zlab_LicenseAgreementDateAndYear	2020-12
License Agreement Date And Year	zlab_LicenseAgreementDateAndYear	2020-12
License Agreement Date And Year	zlab_LicenseAgreementDateAndYear	2021-01
Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturn	$ 47,555,000
Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturn	17,152,000
Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturn	135,490,000
Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturn	37,567,000
Milestone payable upon achievement of specified clinical regulatory sales milestone	zlab_MilestonePayableUponAchievementOfSpecifiedClinicalRegulatorySalesMilestone	590,000
Milestone payable upon achievement of specified clinical regulatory sales milestone	zlab_MilestonePayableUponAchievementOfSpecifiedClinicalRegulatorySalesMilestone	152,000
Equity Securities With Readily Determinable Fair Value Amount	zlab_EquitySecuritiesWithReadilyDeterminableFairValueAmount	20,070,000
Equity Securities With Readily Determinable Fair Value Amount	zlab_EquitySecuritiesWithReadilyDeterminableFairValueAmount	20,070,000
Milestone payments upfront fee	zlab_MilestonePaymentsUpfrontFee	25,000
Milestone payments upfront fee	zlab_MilestonePaymentsUpfrontFee	35,000
Up Front Fees For License Agreement Accrued	zlab_UpFrontFeesForLicenseAgreementAccrued	25,000,000
Up Front Fees For License Agreement Accrued	zlab_UpFrontFeesForLicenseAgreementAccrued	65,000,000
Milestone Payment Accrued	zlab_MilestonePaymentAccrued	3,500,000
Milestone Payment Accrued	zlab_MilestonePaymentAccrued	12,000,000
Milestone Payment Accrued	zlab_MilestonePaymentAccrued	3,000,000
Amortization Of Deferred Income	zlab_AmortizationOfDeferredIncome	(234,000)
Amortization Of Deferred Income	zlab_AmortizationOfDeferredIncome	(234,000)
Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebates	4,452,000
Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebates	2,501,000
Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebates	35,349,000
Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates	zlab_RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebates	3,703,000
Non Cash Payables For Intangible Assets	zlab_NonCashPayablesForIntangibleAssets	24,000
Non Cash Payables For Intangible Assets	zlab_NonCashPayablesForIntangibleAssets	$ 21,000
Number Of Molecules	zlab_NumberOfMolecules	2
Inventory Write Down Value	zlab_InventoryWriteDownValue	$ 112,000
Inventory Write Down Value	zlab_InventoryWriteDownValue	402,000
Inventory Write Down Value	zlab_InventoryWriteDownValue	7,000
Inventory Write Down Value	zlab_InventoryWriteDownValue	0
Increase Decrease In Long Term Deposits	zlab_IncreaseDecreaseInLongTermDeposits	39,000
Increase Decrease In Long Term Deposits	zlab_IncreaseDecreaseInLongTermDeposits	474,000
Loss On Fair Value Changes Of Equity Investment With Readily Determinable Fair Value	zlab_LossOnFairValueChangesOfEquityInvestmentWithReadilyDeterminableFairValue	9,930,000
Loss On Fair Value Changes Of Equity Investment With Readily Determinable Fair Value	zlab_LossOnFairValueChangesOfEquityInvestmentWithReadilyDeterminableFairValue	0
Payables For Purchase Of Property And Equipment Current	zlab_PayablesForPurchaseOfPropertyAndEquipmentCurrent	1,797,000
Payables For Purchase Of Property And Equipment Current	zlab_PayablesForPurchaseOfPropertyAndEquipmentCurrent	788,000
Development Cost Sharing Payment	zlab_DevelopmentCostSharingPayment	75,000,000
Increase Decrease Through Shares Issue Cost Equity	zlab_IncreaseDecreaseThroughSharesIssueCostEquity	(40,000)
Increase Decrease Through Shares Issue Cost Equity	zlab_IncreaseDecreaseThroughSharesIssueCostEquity	(40,000)
Increase Decrease Through Shares Issue Cost Equity	zlab_IncreaseDecreaseThroughSharesIssueCostEquity	13,000
Increase Decrease Through Shares Issue Cost Equity	zlab_IncreaseDecreaseThroughSharesIssueCostEquity	13,000
Increase Decrease Through Shares Issue Cost Equity	zlab_IncreaseDecreaseThroughSharesIssueCostEquity	2,000
Increase Decrease Through Shares Issue Cost Equity	zlab_IncreaseDecreaseThroughSharesIssueCostEquity	2,000
Future Cash Payment	zlab_FutureCashPayment	25,000,000
Non Cash Payables For Public Offering Costs	zlab_NonCashPayablesForPublicOfferingCosts	4,909,000
Inventory Reverses Value	zlab_InventoryReversesValue	7,000
Inventory Reverses Value	zlab_InventoryReversesValue	0
Prepayments For Equipment	zlab_PrepaymentsForEquipment	1,129,000
Prepayments For Equipment	zlab_PrepaymentsForEquipment	274,000
Proceeds From Issuance Public Offering	zlab_ProceedsFromIssuancePublicOffering	818,874,000
Proceeds From Issuance Public Offering	zlab_ProceedsFromIssuancePublicOffering	1,025,970,000
Increase Decrease In Operating Lease Liabilities	zlab_IncreaseDecreaseInOperatingLeaseLiabilities	(3,834,000)
Increase Decrease In Operating Lease Liabilities	zlab_IncreaseDecreaseInOperatingLeaseLiabilities	(2,335,000)
Noncash Research And Development Expenses	zlab_NoncashResearchAndDevelopmentExpenses	$ 62,250,000
Number of programs	zlab_NumberOfPrograms	4
Non Cash Lease Expenses	zlab_NonCashLeaseExpenses	$ 4,595,000
Non Cash Lease Expenses	zlab_NonCashLeaseExpenses	3,251,000
Other Payables Current Liabilities	zlab_OtherPayablesCurrentLiabilities	8,170,000
Other Payables Current Liabilities	zlab_OtherPayablesCurrentLiabilities	4,567,000
Employee taxes paid related to net share settlement of equity awards	zlab_EmployeeTaxesPaidRelatedToNetShareSettlementOfEquityAwards	(3,467,000)
Potential Development Regulatory and Sales Based Milestone [Member]
Additional Milestone Payments	zlab_AdditionalMilestonePayments	336,000,000
Future Contingent Milestone Payments To Be Made Upon Achievement	zlab_FutureContingentMilestonePaymentsToBeMadeUponAchievement	146,000,000
Future Contingent Milestone Payments To Be Made Upon Achievement	zlab_FutureContingentMilestonePaymentsToBeMadeUponAchievement	211,000,000
Future Contingent Milestone Payments To Be Made Upon Achievement	zlab_FutureContingentMilestonePaymentsToBeMadeUponAchievement	$ 481,500,000

Long-term investments - Additional Information (Details) ¥ in Thousands, $ in Thousands	Jul. 31, 2021 USD ($)	Jun. 30, 2017 CNY (¥) item
Equity And Cost Method Investments
Number of third-parties		3
Capital contribution commitment	$ 30,000	¥ 26,250

Print Document View Excel Document
Notes Details Long-term investments - Additional Information (Details) Restricted Net Assets (Details) Uncategorized Uncategorized Items - d208371d10q_htm.xml All Reports